Interestingly, the study of AML patients undergoing allo-HSCT showed that patients achieving a remission status display a CD8+ T-lymphocyte population more advanced in maturation and with a stronger cytotoxicity signature; these CD8+ lymphocytes were characterized by high GPR56 expression; in responding patients, the levels of GPR56 expression increase after allo-HSCT [131,132]. This evidence concerns the gene CD8A and acute myeloid leukemia.